Market Intelligence Resource | January 28, 2011
FDA Executive Summary: Neurological Devices Panel Meeting to Discuss the Classification of Electroconvulsive Therapy Devices
January 28, 2011 The U.S. Food and Drug Administration (FDA) advisory panel met on January 27 and 28th to discuss lowering the devices used for electroconvulsive therapy (ECT) from Class III devices to Class II devices. The advisory panel considered clinical studies and public comments on reclassifying the devices. Download the Report . . .
